2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106415
    Terflavoxate 86433-40-1 98%
    Terflavoxate is a flavone derivative with spasmolytic properties. Terflavoxate has Ca2+-antagonistic effect is mainly responsible for Terflavoxate smooth muscle relaxant properties. Terflavoxate has the potential for overactive detrusor research.
    Terflavoxate
  • HY-106424
    Soretolide 130403-08-6 98%
    Soretolide is an antiepileptic agent. Soretolide is effective in maximal electroshock-induced seizure (MES) test in rodents. Soretolide inhibits metabolism of Phenytoin (HY-B0448). Soretolide exhibits a good pharmacokinetic character in rats model.
    Soretolide
  • HY-106437
    ELB-139 188116-08-7 98%
    ELB-139 is a progesterone analogue. ELB-139 is a GABAA receptor partial agonist. ELB-139 has anxiolytic and anticonvulsant activity. ELB-139 induces increase of extracellular 5-HT in the striatum and the medial prefrontal cortex of rats.
    ELB-139
  • HY-106504
    Aganodine 86696-87-9 98%
    Aganodine is a guanidine that activates presynaptic imidazoline receptors and can inhibit electrically evoked [3H]-norepinephrine release.
    Aganodine
  • HY-106644
    Femoxetine 59859-58-4 98%
    Femoxetine is a serotonin (5-HT) inhibitor with antidepressant properties. Femoxetine increases serotonin levels in the brain by preventing serotonin from being reabsorbed by nerve cells, resulting in increased concentrations of the neurotransmitter in the synaptic gap, which enhances serotonin signaling. Femoxetine can be used to study the role of serotonin in depression and other emotional disorders, and how 5-HT reuptake inhibitors affect mood and behavior.
    Femoxetine
  • HY-106747
    Ralitoline 93738-40-0 98%
    Ralitoline is a sodium channel blocker with IC50 of 2 μM. Ralitoline has anticonvulsant activity.
    Ralitoline
  • HY-106779
    Tamolarizine hydrochloride 93035-33-7 99.07%
    Tamolarizine hydrochloride is a calcium channel blocker. Tamolarizine hydrochloride crosses the blood-brain barrier and antagonizes the effects of calcium on neurons. Tamolarizine hydrochloride can be used in nervous system research.
    Tamolarizine hydrochloride
  • HY-106807
    Litoxetine 86811-09-8 98%
    Litoxetine (SL 81.0385) is a selective 5-HT uptake inhibitor. Litoxetine is a 5-HT3 receptor antagonist with a Ki of 85 nM for cerebral 5-HT3 receptors. Litoxetine is an antidepressant and has antiemetic properties.
    Litoxetine
  • HY-10684R
    Pridopidine (Standard) 346688-38-8 98%
    Pridopidine (Standard) is the analytical standard of Pridopidine. This product is intended for research and analytical applications. Pridopidine, a dopamine (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor (S1R) with Ki between 70 and 80 nM, which is ~100× higher than its affinity toward D2R.
    Pridopidine (Standard)
  • HY-106874
    Delequamine 119905-05-4 98%
    Delequamine (RS-15385-197) is an orally active and selective α2-adrenergic receptor antagonist with a pKi of 9.5 for α2-adrenoceptors in rat cortex. Delequamine shows >1000 fold selectivity against 5-HT1A receptors and α1-adrenoceptors. Delequamine can be used for the study of erectile dysfunction.
    Delequamine
  • HY-106875
    Saripidem 103844-86-6 98%
    Saripidem is a non-selective ligand for ω modulatory sites of GABA receptor.
    Saripidem
  • HY-106956
    Lubazodone 161178-07-0 98%
    Lubazodone is a selective serotonin reuptake inhibitor and can be used for study of depression.
    Lubazodone
  • HY-10704R
    PTP1B-IN-1 (Standard) 612530-44-6 98%
    PTP1B-IN-1 (Standard) (PTP1B inhibitor (Standard)) is the analytical standard of PTP1B-IN-1 (HY-10704). This product is intended for research and analytical applications. PTP1B-IN-1 (Compound 7a) is a small molecule inhibitor of PTP1B with an IC50 value of 1.6 mM. It is often used as the mother core for derivatives of analogues.
    PTP1B-IN-1 (Standard)
  • HY-10715R
    SSR504734 (Standard) 615571-23-8 98%
    SSR504734 (Standard) is the analytical standard of SSR504734 (HY-10715). This product is intended for research and analytical applications. SSR504734 is an orally active, selective and reversible inhibitor of human, rat, and mouse GlyT1 (IC50=18, 15, and 38 nM, respectively). SSR504734 shows anti-schizophrenia, anti-anxiety and anti-depression activities.
    SSR504734 (Standard)
  • HY-107510
    YM-230888 446257-23-4 98%
    YM-230888 is an orally active, selective and allosteric mGlu1 receptor antagonist with a Ki of 13 nM. YM-230888 inhibits mGlu1-mediated inositol phosphate production in rat cerebellar granule cells with an IC50 of 13 nM. YM-230888 shows antinociceptive response in Streptozotocin (HY-13753)-induced hyperalgesia models. YM-230888 significantly reduces pain parameters in complete Freund's adjuvant (HY-153808)-induced arthritic pain models.
    YM-230888
  • HY-107525
    (±)-HIP-A 227619-64-9 98%
    (±)-HIP-A is a non-competitive excitatory amino acid transporter (EAAT) blocker that effectively blocks Glu uptake (IC50=17-18 μM). (±)-HIP-A is also a lead compound against ischemia-induced neuronal degeneration. (±)-HIP-A can be used in the study of neurological diseases.
    (±)-HIP-A
  • HY-107556
    VUF 5681 dihydrobromide 639089-06-8 98%
    VUF 5681 dihydrobromide is a neutral antagonist of histamine H3 receptor. VUF 5681 dihydrobromide also has partial agonist function of H3 receptor. VUF 5681 dihydrobromide blocks the effects of Thioperamide (HY-12206). VUF 5681 dihydrobromide is used in central nervous system disease research.
    VUF 5681 dihydrobromide
  • HY-107668
    TC-1698 dihydrochloride 787587-06-8 98%
    TC-1698 dihydrochloride is a selective α7 nicotinic acetylcholine receptors agonist with EC50 value of 0.16 μM and 0.46 μM for monkey α7 nicotinic receptor and human α7 nicotinic receptor, respectively. TC-1698 dihydrochloride improves memory and has neuroprotective effects. TC-1698 dihydrochloride can be used for Alzheimer's disease research.
    TC-1698 dihydrochloride
  • HY-107679
    SR 16584 1150153-86-8 98%
    SR 16584 is a selective antagonist of α3β4 nAChR with an IC50 of 10.2 μM.
    SR 16584
  • HY-107680
    3-Pyr-Cytisine 948027-43-8 98%
    3-Pyr-Cytisine (3-Pyr-Cyt) is a cytisine derivative. 3-Pyr-Cytisine is a very weak α4β2 nAChR partial agonist that has been studied as an antidepressant.
    3-Pyr-Cytisine
Cat. No. Product Name / Synonyms Application Reactivity